Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 6/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710769 | 0.92 | CNR1 (0.61) | PTGESALOX5NR3C1ALDH1A1LMNA | |
| SCHEMBL3376969 | 0.87 | LMNA (0.60) | PTGESALOX5NR3C1NR1I2ALDH1A1 | |
| SCHEMBL13064477 | 0.84 | POLB (0.65) | PTGESALOX5NR3C1NR1I2ALDH1A1 | |
| SCHEMBL3278663 | 0.82 | PTGES (0.84) | PTGESALOX5NR3C1NR1I2RORC | |
| SCHEMBL3279243 | 0.81 | FNTA (0.65) | PTGESALOX5NR1I2ALDH1A1LMNA | |
| SCHEMBL3379944 | 0.80 | MAPT (0.55) | PTGESNR3C1ALDH1A1LMNAESR1 | |
| SCHEMBL3378945 | 0.80 | LMNA (0.56) | ALDH1A1LMNAL3MBTL1PGR | |
| SCHEMBL1169287 | 0.79 | LMNA (0.73) | PTGESALOX5NR3C1ALDH1A1LMNA | |
| SCHEMBL2776393 | 0.77 | TP53 (0.72) | PTGESALOX5NR3C1ALDH1A1PGR | |
| SCHEMBL13064400 | 0.77 | POLB (0.59) | PTGESALOX5NR3C1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | PTGES 3030/4885ALOX5 4481/4885NR3C1 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.